Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21060929 | 0.85 | PLA2G2A (0.62) | PLA2G2ATP53TSHRPLA2G4BBLM | |
| SCHEMBL21060971 | 0.85 | GPR84 (0.48) | PLA2G2AALDH1A1TP53TSHRPLA2G4B | |
| SCHEMBL21061098 | 0.81 | PLA2G2A (0.45) | PLA2G2ATP53TSHRPLA2G4BBLM | |
| SCHEMBL21061135 | 0.80 | MEN1 (0.48) | PLA2G2AALDH1A1TP53TSHR | |
| SCHEMBL21061253 | 0.79 | PLA2G2A (0.42) | PLA2G2ATP53TSHRSMPD1PLA2G4B | |
| SCHEMBL9147935 | 0.78 | BAZ2B (0.51) | BAZ2BBAZ2AALDH1A1 | |
| SCHEMBL9151583 | 0.78 | BAZ2B (0.51) | BAZ2BBAZ2AALDH1A1 | |
| SCHEMBL21061003 | 0.78 | GPR84 (0.42) | PLA2G2AALDH1A1TP53TSHR | |
| SCHEMBL21061002 | 0.78 | GPR84 (0.42) | PLA2G2AALDH1A1TP53TSHR | |
| SCHEMBL21061124 | 0.77 | GPR84 (0.44) | PLA2G2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL SA (ES) | 2021-07-22 | — | — | US | disclosed |
| CN-111886230-A | Pyrrole derivatives as ACC inhibitors | 阿尔米雷尔有限公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-3724182-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | Almirall S.A. (ES) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019115405-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL, S.A. (ES) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ACACA, ACACB, PCCA | PLA2G2A 4050/4885BAZ2B 2995/4885BAZ2A 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.